Cogent Biosciences (COGT) Cash from Investing Activities (2017 - 2026)

Cogent Biosciences (COGT) has 9 years of Cash from Investing Activities data on file, last reported at -$36.5 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 152.55% year-over-year to -$36.5 million in Q1 2026; TTM through Mar 2026 was -$505.4 million, a 574.02% decrease from a year earlier, with the FY2025 full-year figure at -$399.5 million, down 1143.8% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$36.5 million, up from -$322.8 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for COGT reached as high as $69.4 million in Q1 2025 and fell as low as -$322.8 million in Q4 2025.
• Historically, Cash from Investing Activities has averaged -$36.5 million across 5 years, with a median of -$441000.0 in 2022.
• Across the five-year window, Cash from Investing Activities plunged 12930.44% in 2022 and surged 13679.14% in 2023, its largest moves.
• Year by year, Cash from Investing Activities stood at $28.4 million in 2022, then sank by 63.08% to $10.5 million in 2023, then jumped by 487.96% to $61.7 million in 2024, then sank by 623.37% to -$322.8 million in 2025, then soared by 88.7% to -$36.5 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$36.5 million in Q1 2026, -$322.8 million in Q4 2025, and -$155.0 million in Q3 2025.